| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | UTR, UTR2, GPR14, UR-2-R |
| WB Predicted band size | 42 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human UTS2R |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于UTS2R(Urotensin II受体)抗体的3篇文献摘要示例，基于领域内相关研究方向的典型内容整理：
---
1. **文献名称**：*"Characterization of a Novel Monoclonal Antibody Targeting Urotensin II Receptor for Cardiovascular Disease Research"*
**作者**：Smith A, et al.
**摘要**：研究团队开发了一种针对UTS2R的单克隆抗体，验证了其在人血管平滑肌细胞中的特异性结合能力。该抗体通过免疫组化和流式细胞术证实了UTS2R在动脉粥样硬化模型中的表达上调，并用于探索受体激活与血管收缩的关系。
2. **文献名称**：*"UTS2R Antibody-Based Pharmacological Inhibition Attenuates Renal Fibrosis in Diabetic Mice"*
**作者**：Chen L, et al.
**摘要**：研究利用UTS2R中和抗体，在小鼠糖尿病肾病模型中阻断Urotensin II信号通路。结果显示，抗体治疗显著减少肾纤维化标志物(如α-SMA和胶原蛋白)表达，表明UTS2R可能成为慢性肾病治疗的靶点。
3. **文献名称**：*"Development of a High-Affinity Polyclonal Antibody for UTS2R Localization in Human Tumor Tissues"*
**作者**：Garcia R, et al.
**摘要**：通过免疫兔获得多克隆抗体，用于检测UTS2R在多种癌症组织中的分布。免疫荧光和Western blot分析显示，抗体特异性识别肿瘤微血管内皮细胞中的UTS2R，提示其可能参与肿瘤血管生成调控。
---
**备注**：上述文献为示例性内容，实际研究中建议通过PubMed或Web of Science以关键词“UTS2R antibody”“Urotensin II receptor antagonist”检索最新论文，并关注抗体应用场景(如疾病模型、信号机制等)。部分研究可能侧重受体功能而非抗体本身，需结合实验目的筛选。
The UTS2R antibody targets the urotensin II receptor (UTS2R), a G protein-coupled receptor (GPCR) that binds urotensin II (UII), a potent cyclic peptide involved in diverse physiological processes. UTS2R is widely expressed in cardiovascular tissues, the central nervous system, kidneys, and endocrine organs, playing roles in vasoconstriction, blood pressure regulation, inflammation, and cell proliferation. Dysregulation of the UII-UTS2R axis is implicated in pathologies such as hypertension, heart failure, atherosclerosis, and chronic kidney disease, making it a focus for therapeutic research.
UTS2R antibodies are critical tools for studying receptor localization, expression levels, and signaling mechanisms in both normal and diseased states. They enable techniques like immunohistochemistry, Western blotting, and flow cytometry, aiding in the exploration of UTS2R’s tissue-specific functions and interactions. Additionally, these antibodies support drug discovery by identifying receptor modulators or evaluating therapeutic candidates in preclinical models. Challenges in developing UTS2R antibodies include ensuring specificity due to structural similarities among GPCRs and optimizing stability for experimental reproducibility. Recent advances in antibody engineering, such as monoclonal and recombinant formats, have improved their utility in translational research. By elucidating UTS2R’s role in disease pathways, these antibodies contribute to potential diagnostic and therapeutic innovations, particularly in cardiovascular and metabolic disorders.
×
